Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 2/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 8/20 | 0.45 |
| ▸ | BRAF | P15056 | 8/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | GPR183 | P32249 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17790980 | 0.90 | SMO (0.54) | SMOSCN9AHDAC1 | |
| SCHEMBL1018456 | 0.90 | SMO (0.54) | SMOSCN9AHDAC1 | |
| SCHEMBL12727146 | 0.90 | SCN9A (0.49) | SMOSCN9APGRGPR183HDAC1 | |
| SCHEMBL26033198 | 0.86 | RAF1 (0.60) | RAF1BRAF | |
| SCHEMBL26037944 | 0.85 | KIF18A (0.49) | SMOSCN9ARAF1BRAFPGR | |
| SCHEMBL26033178 | 0.84 | L3MBTL1 (0.58) | RAF1BRAFHDAC1 | |
| SCHEMBL26035522 | 0.83 | KDM4E (0.45) | SCN9ARAF1BRAF | |
| SCHEMBL26035159 | 0.82 | ABL1 (0.46) | RAF1BRAFHDAC1 | |
| SCHEMBL26035128 | 0.82 | RAD52 (0.54) | RAF1BRAFHDAC1 | |
| SCHEMBL26037325 | 0.81 | KDM4E (0.65) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | SMO 3/4885SCN9A 4128/4885RAF1 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.